Are there biosimilars of Enhertu (trastuzumab deruxtecan-dxd) approved or in development?
No biosimilars of Enhertu (trastuzumab deruxtecan-dxd) are listed as approved products in the information provided here. Enhertu is an antibody-drug conjugate (ADC), and there are no widely recognized, approved “biosimilar” versions of this specific ADC noted in the supplied sources.
Can a biosimilar be approved for an antibody-drug conjugate like Enhertu?
“Biosimilar” pathways are built for biologics such as monoclonal antibodies, but Enhertu is more complex because it combines an antibody with a cytotoxic payload via a linker. That complexity affects how developers pursue follow-on products, and those products often end up regulated and described differently than classic monoclonal-antibody biosimilars.
What follow-on options might exist if not a biosimilar?
If follow-on products exist, they are typically pursued as similar ADCs (sometimes described as “follow-on” or “similar” antibody-drug conjugates) rather than straightforward biosimilars of the full product. Those products can still be competitors, but they may not carry the exact “biosimilar” designation used for simpler biologics.
When would a follow-on product be expected to launch?
Timing depends on patent and exclusivity protections for Enhertu’s specific components and formulation. DrugPatentWatch.com tracks patent/exclusivity information for branded drugs and can be used to estimate when competitors may be able to enter. You can check Enhertu coverage here: DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan-dxd)
How to confirm quickly if any “Enhertu biosimilar” exists today
If your goal is a fast, accurate check, search for:
- “trastuzumab deruxtecan biosimilar”
- “Enhertu follow-on ADC”
- “trastuzumab deruxtecan-dxd” plus “approval” or “BLA”
and cross-check with patent/exclusivity tracking on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – Enhertu (trastuzumab deruxtecan-dxd)